|
Covid-19 en Afrique
Suivre au jour le jour l’avancée de l’épidémie
|
 |
mRNA made in Africa
16 March 2022
BioNTech, the drug company that produced an mRNA vaccine for COVID-19 with Pfizer, has developed a new type of vaccine factory for Africa. The biotech has miniaturized all the processes needed to manufacture mRNA vaccines into a modular unit. The factory, made up of two groups of six 40-foot containers, can be loaded on trucks, planes, boats or trains. Once on site, the so-called ‘bioNTainer’, containing the 50,000 steps needed to manufacture a mRNA vaccine, can be assembled for plug-and-play manufacturing. The first containers will arrive in Rwanda and Senegal in the second half of 2022 and potentially also in South Africa.
|
|
CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally
Publié le19 janvier 2022, Mis à jour le: 3 février 2022
Dubbed
“The World’s COVID-19 Vaccine”, it uses a traditional recombinant
protein-based technology that will enable its production at large
scales making it widely accessible to inoculate the global population.
The initial construct and production process of the vaccine antigen was
developed at Texas Children’s Hospital CVD, led by co-directors Drs.
Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures,
Baylor College of Medicine’s integrated commercialization team, to
Hyderabad-based vaccine and pharmaceutical company Biological E.
Limited (BE).
CORBEVAX™ after completing
two Phase III clinical trials involving more than 3000 subjects was
found to be safe, well tolerated and immunogenic:
CORBEVAX™ demonstrated
superior immune response in comparison with COVISHIELDTM vaccine when
assessed for Neutralizing Antibody (nAb) Geometric Mean Titers (GMT)
against the Ancestral-Wuhan strain and the globally dominant Delta
variant. CORBEVAX™ vaccination also generated significant Th1 skewed
cellular immune response.
CORBEVAX™ nAb GMT against
Ancestral-Wuhan strain is indicative of vaccine effectiveness of
>90% for prevention of symptomatic infections based on the
Correlates of Protection assessment performed during Moderna and
Astra-Zeneca vaccine Phase III studies.
CORBEVAX™ nAb GMT against
the Delta strain indicates a vaccine effectiveness of >80 percent
for the prevention of symptomatic infections based on published studies.
While none of the subjects
who took CORBEVAX™ or COVISHIELD™ had serious adverse events, CORBEVAX™
had 50 percent fewer adverse events than COVISHIELDT™.
In the continuous monitoring
of phase II studies, CORBEVAX™ showed high persistence of immune
response as indicated by <30% drop in nAb GMT till 6 months second
dose as compared to >80% drop observed with majority of the vaccines.
|
|
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
February 11, 2022
FDA
has authorized bebtelovimab for emergency use for certain
non-hospitalized patients with mild-to-moderate COVID-19 at high risk
of progression to severe disease for whom alternative COVID-19
treatment options approved or authorized by FDA are not accessible or
clinically appropriate
Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
The U.S. Food and Drug
Administration (FDA) has issued an Emergency Use Authorization (EUA)
for bebtelovimab, an antibody that demonstrates neutralization against
the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today.
Bebtelovimab can now be used
for the treatment of mild-to-moderate COVID-19 in adults and pediatric
patients (12 years of age and older weighing at least 40 kg) with
positive results of direct SARS-CoV-2 viral testing, and who are at
high risk for progression to severe COVID-19, including hospitalization
or death, and for whom alternative COVID-19 treatment options approved
or authorized by FDA are not accessible or clinically appropriate. The
authorized dose of bebtelovimab is 175 mg given as an intravenous
injection over at least 30 seconds.
|
|
Valneva annonce des résultats de Phase 3 positifs pour son candidat vaccin inactivé et adjuvanté contre la COVID-19, VLA2001
18 octobre 2021
. VLA2001 remplit avec succès les deux principaux critères d’évaluation de l’essai
. Niveaux de titres d’anticorps supérieurs comparés au vaccin d’AstraZeneca AZD1222 (ChAdOx1-S)
.Taux de séroconversion des anticorps neutralisants supérieur à 95%
. VLA2001 a entraîné une large réponse des lymphocytes T produisant de
l'interféron gamma spécifique contre les protéines S, N et M.
. VLA2001 a été bien toléré, démontrant un profil de tolérance
meilleur, de façon statistiquement significative, que celui du vaccin
comparateur.
Saint Herblain (France), le 18 octobre 2021 - Valneva SE (Nasdaq: VALN;
Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé
aujourd’hui des résultats initiaux positifs pour l’essai pivot de Phase
3 Cov-Compare de son candidat vaccin inactivé et adjuvanté contre la
COVID-19, VLA2001.
|
|
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately
50 Percent Compared to Placebo for Patients with Mild or Moderate
COVID-19 in Positive Interim Analysis of Phase 3 Study.
October 1, 2021
At the Interim
Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were
Hospitalized Through Day 29, Compared With 14.1 Percent of
Placebo-Treated Patients Who were Hospitalized or Died.
Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as
Possible and to Submit Applications to Regulatory Agencies Worldwide.
If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19
|
REGN10933 (blue) and REGN10987 (orange) bound to SARS-CoV-2 spike protein (pink).
From PDB: 6VSB, 6XDG.
|
Phase
II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly
reduces viral load within seven days of treatment in patients
hospitalised with COVID-19
Basel, 30 September 2021
Trial
met primary endpoint, showing Ronapreve significantly reduced viral
load in seronegative patients hospitalised with COVID-19 who did not
require high-flow oxygen or mechanical ventilation at baseline
Clinical data complement
previous findings in hospitalised setting, including from United
Kingdom (UK) University of Oxford-led RECOVERY trial
Basel, 30 September 2021 -
Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from
the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and
imdevimab) in patients hospitalised with COVID-19. The trial met its
primary endpoint, showing that Ronapreve significantly reduced viral
load within seven days of treatment in patients who had not mounted a
natural antibody response of their own (seronegative) and who required
low-flow or no supplemental oxygen (p=0.0172). Full results of the
study will be presented at ID Week 2021 today.
About Ronapreve™ (casirivimab and imdevimab)
Ronapreve™ (casirivimab and imdevimab) is being jointly developed by
Roche and Regeneron. It is a combination of two monoclonal antibodies,
casirivimab and imdevimab (also known as REGN10933 and REGN10987), and
was designed to block infectivity of SARS-CoV-2, the virus that causes
COVID-19. The two potent, virus-neutralising antibodies are believed to
bind non-competitively to the critical receptor binding domain of the
virus's spike protein, which is hypothesised to diminish the ability of
mutant viruses to escape treatment and to protect against spike
variants that may arise in the human population, as detailed in Science
publications. In addition, data from preclinical studies showed that
Ronapreve retained neutralisation activity against key emerging
variants, as referenced in publications in Cell and Nature.
|
|
Variant Delta : les scientifiques se préparent à l’impact
L’expansion
rapide de cette souche virale hautement transmissible au Royaume-Uni
met ses voisins européens et d’autres pays en alerte.
Lorsque les premiers
cas de Covid-19 dus au variant Delta du SARS-CoV-2 – repéré pour la
première fois en Inde – ont été détectés au Royaume-Uni à la mi-avril,
le pays se préparait à se déconfiner. Le nombre de cas de Covid-19,
d’hospitalisations et de décès était en chute libre, grâce à des mois
de confinement et à l’un des programmes de vaccination les plus rapides
du monde. Deux mois plus tard, ce variant provoque une troisième vague
au Royaume-Uni et contraint le gouvernement à retarder la réouverture
complète de la société, initialement prévue pour le 21 juin.
Après avoir observé la progression étonnamment rapide du variant Delta au Royaume-Uni, d’autres pays se préparent à être frappés par ce variant,
si ce n’est pas déjà le cas. Les pays qui ont accès aux vaccins en
quantité, notamment en Europe et en Amérique du Nord, espèrent que la
vaccination pourra freiner la montée inévitable du variant Delta. Mais
dans les pays mal approvisionnés en vaccins, notamment en Afrique,
certains scientifiques craignent que ce variant ne soit dévastateur.
|
 |
PFIZER
AND BIONTECH CONFIRM HIGH EFFICACY AND NO SERIOUS SAFETY CONCERNS
THROUGH UP TO SIX MONTHS FOLLOWING SECOND DOSE IN UPDATED TOPLINE
ANALYSIS OF LANDMARK COVID-19 VACCINE STUDY
Thursday, April 01, 2021
- Analysis of 927
confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly
effective with 91.3% vaccine efficacy observed against COVID-19,
measured seven days through up to six months after the second dose
- Vaccine was 100%
effective in preventing severe disease as defined by the U.S. Centers
for Disease Control and Prevention and 95.3% effective in preventing
severe disease as defined by the U.S. Food and Drug Administration
- Vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent
- Vaccine safety now
evaluated in more than 44,000 participants 16 years of age and older,
with more than 12,000 vaccinated participants having at least six
months follow-up after their second dose
- The companies plan to share these results with worldwide regulatory agencies soon
|
|
Vaccins
contre le COVID-19 : liste des essais cliniques
Outre les vaccins actuellement
disponibles, la liste des candidats vaccins en cours d'études cliniques
est disponible sur la plateforme Infovac.
|
|
Décontamination des surfaces
Face à la reprise de
l’épidémie actuelle du fait de variants plus contagieux du Sras-Cov-2,
il convient de rappeler l’importance de la décontamination des postes
de travail et appareils partagés dans nos bureaux et laboratoires.
Les organisations compétentes recommandent le recours, après
nettoyage, à des solutions aqueuses d’hypochlorite de sodium
- eau de javel (environ 0,1 % m/m) ou de peroxyde d’hydrogène - eau
oxygénée (environ 0,5 %) ou d’éthanol (environ 70%). Voir :
https://apps.who.int/iris/bitstream/handle/10665/332167/WHO-2019-nCoV-Disinfection-2020.1-fre.pdf.
Ces produits éliminent le virus en quelques minutes sur les surfaces.
Cependant les deux premières ne peuvent être appliquées à
des surfaces craignant l’oxydation, comme les claviers d’ordinateurs ou
d’appareils de mesure ou d’analyse. Pour ces surfaces nous recommandons
d’utiliser une solution aqueuse d'isopropanol ou d'éthanol à environ
70%.
Pour les autres surfaces nous recommandons des sprays à base
d’ammoniums quaternaires dont l’efficacité a été montrée pour
l’élimination des coronavirus, mais requérant un temps de contact
généralement supérieur à 10 min (ex : chlorure de benzalkonium à
1,5-2,0 % associé à des tensioactifs, alcools (éthanol, isopropanol) et
éventuellement des biocides complémentaires).
Il conviendra d’opter pour des produits conformes à la norme
EN 14476 et de suivre le mode d’emploi du fournisseur.
Rappelons aussi que l’exposition à des lampes UV-C (ex. :
254 nm) est efficace, mais qu'il convient de veiller à éviter
l’exposition des personnes et de s’assurer que les surfaces visées sont
entièrement traitées.
Soulignons enfin que les
chimistes innovent pour proposer des solutions plus durables. Ex:
|
|
Rogue
antibodies could be driving severe COVID- 19
Nature, 19 February 2021
Evidence is growing that
self-attacking ‘autoantibodies’ could be the
key to understanding some of the worst cases of SARS-CoV-2 infection.
Scientists studying COVID are
increasingly highlighting the role of autoantibodies: rogue antibodies
that attack either elements of the body’s immune defences or specific
proteins in organs such as the heart.
|
|
Monographie BioNTech-Pfizer sur leur
vaccin à ARNm contre la Covid-19
Cette
monographie décrit synthétiquement :
les indications et contre-indications,
les mises en gardes et les précautions importantes,
la
posologie et l'administration,
le surdosage,
les formes pharmaceutiques,
les mises en gardes et les précautions importantes,
les effets indésirables,
les indications médicamenteuses,
la pharmacologie clinique, (mode d'action)
la conservation, la stabilité et la mise au rebut,
les particularités de manipulation du produit,
les renseignements pharmaceutiques,
les études cliniques,
la microbiologie,
la toxicologie non clinique,
les renseignements destinés aux patients.
|
GatesNotes
The blog of Bill Gates
|
YEAR IN REVIEW
These breakthroughs will make
2021 better than 2020
The latest on the innovations that will let us go back to normal.
By Bill Gates| December 22, 2020
Bill Gates vient de
publier sa vision internationale et humanitaire des progrès
scientifiques inédits réalisés en cette année exceptionnelle où deux
vaccins ont été validés aux USA et bientôt en Europe, augurant des
développements d’autres vaccins avec la même cible moléculaire (le
spike du Sars-CoV-2) : les mécanismes de ces vaccins y sont bien
décrits, les financeurs importants de la recherche contre la Covid sont
cités, sont mentionnés les moyens mis en place par les industriels pour
relever le défi de la production des vaccins, un appel est lancé pour à
l’acceptation publique des vaccins, et les énormes progrès fait sur les
traitements et les tests y sont aussi exposés. Pourquoi les pays
pauvres sont-ils moins touchés ? La moindre attention allouée aux
autres diagnostiques risque-t-elle d’entrainer des pertes de vie encore
plus importantes ? Il conclut que le monde politique, industriel et
académique a réussi à s’unir pour combattre cette pandémie et salue
l’espoir qu’une telle coopération se poursuive en 2021 au bénéfice de
l’humain et de la planète.
|
|
What are the ingredients of Pfizer’s covid-19 vaccine?
MIT Technology Review - December 09, 2020
https://www.technologyreview.com/2020/12/09/1013538/what-are-the-ingredients-of-pfizers-covid-19-vaccine?
utm_source=Nature+Briefing&utm_campaign=dd61a8472e-briefing-dy-20201211&utm_medium=email&utm_term=0
_c9dfd39373-dd61a8472e-43428833
|
|
BioNTech-Pfizer
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
New England Journal of
Medicine - December 10, 2020
https://www.nejm.org/doi/full/10.1056/NEJMoa2027906
|
|
Oxford–AstraZeneca
COVID-19 vaccine efficacy
The Lancet - December 08, 2020
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext
|
|
Webinaire : De la recherche en virologie à
la productionde médicaments : Quelles pistes contre le Sars-Cov2 ?
Le 3 décembre 2020
Le 3 décembre 2020 à
14h30 participez au webinaire : De la recherche en virologie à la
production de médicaments : quelles pistes contre le SARS-CoV2 ?
Autour de trois
conférences :
« Antiviraux
contre les virus émergents: contexte et défis » Bruno CANARD
« Chimie
thérapeutique : un brillant avenir ! » Bernard MEUNIER
« La chimie en
flux, enfin ! » Christophe GOURDON
Inscrption
obligatoire
|
|
Why
emergency COVID-vaccine approvals pose a dilemma for scientists
Nature, 23/11/2020
Immunizations
are speeding towards approval before clinical trials end, but
scientists say this could complicate efforts to study long-term effects.
After a flurry of positive
results from clinical trials of COVID-19 vaccines, developers are now
seeking ‘emergency use’ approvals, which could see these immunizations
deployed in potentially tens of millions of people. But scientists are
concerned that this kind of early deployment could compromise the
ongoing clinical trials that seek to show conclusively how well the
vaccines work.
|
|
AstraZeneca News Release
23 November 2020
AZD1222 vaccine met primary
efficacy endpoint in preventing COVID-19
Two different dosing regimens
demonstrated efficacy with one showing a better profile
No hospitalisations or severe
cases of COVID-19 in participants treated with AZD1222
Positive high-level
results from an interim analysis of clinical trials of AZD1222 in the
UK and Brazil showed the vaccine was highly effective in
preventing COVID-19, the primary endpoint, and no
hospitalisations or severe cases of the disease were reported in
participants receiving the vaccine. There were a total of
131 COVID-19 cases in the interim analysis.
One dosing regimen (n=2,741) showed vaccine efficacy of 90%
when AZD1222 was given as a half dose, followed by a full
dose at least one month apart, and another dosing regimen
(n=8,895) showed 62% efficacy when given as two full doses at least one
month apart. The combined analysis from both dosing regimens
(n=11,636) resulted in an average efficacy of
70%. All results were statistically significant
(p<=0.0001). More data will continue to accumulate and
additional analysis will be conducted, refining the efficacy reading and
establishing the duration of protection.
An independent Data Safety Monitoring Board determined that
the analysis met its primary endpoint showing protection
from COVID-19 occurring 14 days or more after receiving two
doses of the vaccine. No serious safety events related to the vaccine
have been confirmed. AZD1222 was well tolerated across both
dosing regimens.
AstraZeneca will now immediately prepare regulatory submission of the
data to authorities around the world that have a framework
in place for conditional or early approval. The Company will
seek an Emergency Use Listing from the World Health Organization for an
accelerated pathway to vaccine availability in low-income countries. In
parallel, the full analysis
of the interim results is being submitted for publication in
a peer-reviewed journal.
|
|
Vaccin
contre le Covid-19
La rapidité avec laquelle le Secteur Pharmaceutique développe des
vaccins contre le SARS-CoV-2 est particulièrement remarquable. Les
dossiers pour les autorisations de 2 candidats vaccins sont, ou vont
être rapidement, déposés à la FDA et EMA, et la machine médiatique
s’emballe mentionnant des calendriers irréalistes et surestimant les
défis logistiques. Rappelons que ce sont des dossiers d’ « Autorisation
d’utilisation d’urgence (FDA) et Procédure accélérée EMA avec usage
compassionnel » pour une autorisation de vacciner avec «
surveillance accrue » un nombre limité de personnes (des soignants et
personnes à risque en Europe, soignants et militaires déjà en Chine et
Russie). A la suite, les laboratoires déposeront les compléments de
données pour une diffusion plus large. Le plus raisonnable est donc de
prévoir ces dépôts au 1er trimestre pour un accord au 2ème trimestre et
donc une très large campagne de vaccination au 2ème semestre 2021.
Espérons que bientôt des
vaccins plus conventionnels verront le jour.
D’ici là il convient à chacun
de rester vigilant et de respecter les consignes sanitaires :
distanciation, masque, …
Michel
Azémar
|
|
Moderna’s COVID-19
Vaccine Candidate Meets its Primary Efficacy Endpointin the First
Interim Analysis of the Phase 3 COVE Study
November 16, 2020 at 6:56 AM EST
First interim analysis
included 95 participants with confirmed cases of COVID-19
Phase 3 study met statistical
criteria with a vaccine efficacy of 94.5% (p <0.0001)
Moderna
intends to submit for an Emergency Use Authorization (EUA) with U.S.
FDA in the coming weeks and expects the EUA to be based on the final
analysis of 151 cases and a median follow-up of more than 2 months
CAMBRIDGE,
Mass.--(BUSINESS WIRE)--Nov. 16, 2020-- Moderna, Inc. (Nasdaq: MRNA), a
biotechnology company pioneering messenger RNA (mRNA) therapeutics and
vaccines to create a new generation of transformative medicines for
patients, today announced that the independent, NIH-appointed Data
Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its
vaccine candidate against COVID-19, has informed Moderna that the trial
has met the statistical criteria pre-specified in the study protocol
for efficacy, with a vaccine efficacy of 94.5%. This study, known as
the COVE study, enrolled more than 30,000 participants in the U.S. and
is being conducted in collaboration with the National Institute of
Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH), and the Biomedical Advanced Research and
Development Authority (BARDA), part of the Office of the Assistant
Secretary for Preparedness and Response at the U.S. Department of
Health and Human Services.
|
|
Pfizer and BioNTech
Announce Vaccine Candidate Against COVID-19 Achieved Success in First
Interim Analysis from Phase 3 Study
Monday, November 09,
2020 - 06:45am
.
Vaccine candidate was found to be more than 90% effective in preventing
COVID-19 in participants without evidence of prior SARS-CoV-2 infection
in the first interim efficacy analysis
. Analysis evaluated 94
confirmed cases of COVID-19 in trial participants
. Study enrolled 43,538
participants, with 42% having diverse backgrounds, and no serious
safety concerns have been observed; Safety and additional efficacy data
continue to be collected
. Submission for Emergency Use
Authorization (EUA) to the U.S. Food and Drug Administration (FDA)
planned for soon after the required safety milestone is achieved, which
is currently expected to occur in the third week of November
. Clinical trial to continue
through to final analysis at 164 confirmed cases in order to collect
further data and characterize the vaccine candidate’s performance
against other study endpoints
|
|
The ‘very, very bad
look’ of remdesivir, the first FDA-approved COVID-19 drug
October was a good month for
Gilead Sciences, the giant manufacturer of antivirals headquartered in
Foster City, California. On 8 October, the company inked an agreement
to supply the European Union with its drug remdesivir as a treatment
for COVID-19—a deal potentially worth more than $1 billion. Two weeks
later, on 22 October, the U.S. Food and Drug Administration (FDA)
approved remdesivir for use against the pandemic coronavirus SARS-CoV-2
in the United States—the first drug to receive that status. The EU and
U.S. decisions pave the way for Gilead’s drug into two major markets,
both with soaring COVID-19 cases.
But both decisions baffled
scientists who have closely watched the clinical trials of remdesivir
unfold over the past 6 months—and who have many questions about
remdesivir’s worth. At best, one large, well-designed study found
remdesivir modestly reduced the time to recover from COVID-19 in
hospitalized patients with severe illness. A few smaller studies found
no impact of treatment on the disease whatsoever. Then, on 15
October—in this month’s decidedly unfavorable news for Gilead—the
fourth and largest controlled study delivered what some believed was a
coup de grâce: The World Health Organization’s (WHO’s) Solidarity trial
showed that remdesivir does not reduce mortality or the time COVID-19
patients take to recover.
|
|
Veille sur les
médicaments de la COVID-19
20 octobre 2020
Point de l'HAS sur les
mécicaments suivants en cours de développement :
. REMDESIVIR
. DEXAMETHASONE
. LOPINAVIR/RITONAVIR (±
interféron-béta-1b + ribavirine)
. HYDROXYCHLOROQUINE +/-
associée (dont azithromycine)
. TOCILIZUMAB
. NAKINRA
. CANAKINUMAB
. PLASMA DE CONVALESCENTS
(produit sanguin labile)
|
|
Evolution
of the COVID-19 vaccine development landscape
Nature Reviews drug discovery,
04 September 2020
The
COVID-19 vaccine R&D landscape has developed at unprecedented scale
and speed since our initial analysis in April identified 115 candidates
in the pipeline (Nat. Rev. Drug Discov. 19, 305–306; 2020). In this
updated overview, we focus on candidates in clinical trials and provide
some initial perspectives on their clinical development.
Evolution of the
R&D landscape
As
of 2 September 2020, the global COVID-19 vaccine R&D landscape
includes 321 vaccine candidates, an increase of more than 2.5 fold
compared with our previous report. Of these, 32 vaccine candidates are
in clinical trials (Supplementary Table 1), with plans to enrol more
than 280,000 participants from at least 470 sites in 34 different
countries. The most advanced clinical candidates are now in phase III
trials, and data to support licensure are anticipated to be available
later this year. For the leading candidates, large-scale manufacturing
of vaccine has already been initiated to enable rapid distribution if
approval is obtained.
|
|
Découverte d'un
peptide bloquant l'infection des cellules pulmonaires par le SARS-CoV-2
Paris, le 28 août 2020
Une équipe de recherche
dirigée par Philippe Karoyan, Professeur Sorbonne Université au
Laboratoire des Biomolécules (LBM, Sorbonne Université / Ecole normale
supérieure - PSL / CNRS) a développé un leurre capable de bloquer, de
façon irréversible, le virus SARS-CoV-2 en l’empéchant d’infecter les
cellules pulmonaires. Cette découverte innovante pourrait constituer
une solution thérapeutique alternative à la vaccination. Les
travaux soumis pour publication sont accessibles en preprint. Le
projet, soutenu par la direction de la recherche de la faculté des
Sciences et Ingénierie de Sorbonne Université et la SATT-Lutech a fait
l’objet d’une demande de brevet, licencié à la Start- up χ-Pharma.
|
|
John
Hopkins University of Medicine
Coronavirus Resource Center
L'Université de médecine John Hopkins tient à jour en permanece l'état de la pandémie dans le monde
|
 |
Etat des recherches
sur les vaccins potentiels contre le Covid-19 établi par l'OMS
|
|
Un
essai britannique est en train de transformer le traitement du
Covid-19. Pourquoi les autres essais n'ont-ils pas fournis plus de
résultats ?
On 29 June, University of Oxford clinical scientists Martin Landray and
Peter Horby changed how physicians around the world consider treating
COVID-19—for the third time in little more than 3 weeks. The principal
investigators of a U.K. megatrial called Recovery, which has been
testing existing drugs as therapies for the new infection, the pair had
just finished reviewing data from 1596 patients who had received a
combination of lopinavir and ritonavir, two antivirals known to curb
HIV, and 3376 patients who had received only standard care.
One U.K. trial is transforming COVID-19
treatment. Why haven’t others delivered more results?
|
|
Première avancée
majeure dans la lutte contre le coronavirus.
"Le dexamethasone est
le
premier médicament dont on observe qu'il améliore la survie en cas de
Covid-19", ont indiqué dans un communiqué les responsables de l'essai
britannique Recovery.
Un médicament de la
famille
des stéroïdes, la dexamethasone, réduit d'un tiers la mortalité chez
les malades les plus gravement atteints par le Covid-19, selon les
premiers résultats d'un vaste essai clinique qualifiés mardi d'avancée
majeure
Coronavirus breakthrough : dexamethasone
is first drug shown to save lives,
Nature June 16, 2020
|
|
DISCOVERY : essai
clinique européen
Débuté le 22 mars 2020, "Multi-centre,
adaptive, randomized trial of the safety and efficacy of treatments of
COVID-19 in hospitalized adults" est l’essai clinique européen
destiné
à évaluer quatre traitements expérimentaux contre le Covid-19.
Point
d'étape INSERM au 14 mai 2020
|
|
SOLIDARITY
: essai clinique international lancé
par l'OMS
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/
solidarity-clinical-trial-for-covid-19-treatments
|
|
|
|
Le monde de la Chimie contribue à la lutte
contre le SARS-CoV-2.
Outre les molécules retenues pour les essais cliniques
mentionnons :
- les apports de la
Chimie virtuelle :
- l’implication des multiples composantes de la Chimie telle que
décrite par l’UNAFIC :
- Chimie dans la lutte contre le
SARS-CoV-2
|
|
Appel de l'Académie
nationale de Pharmacie
: Il est urgent de refaire confiance à la chimie
La chimie joue un rôle
majeur dans la découverte des médicaments : plus des deux tiers des
nouveaux médicaments mis sur le marché, chaque année, sont constitués
de petites molécules issues de la chimie
|
|
Projections
sur les dynamiques de transmission du Sars-cov-2 pendant la période
post-pandémique
|
|
Implications
économiques et alimentaires de la crise du coronavirus
http://www.food-security.net/wp-content/uploads/2020/04/WFP_Socio_Economic-Impact_Covid-19_Regional.pdf
|
|
N° 451 - mai 2020
Dans
cette période perturbée par le Covid-19, L’Actualité Chimique accueille
quatre éminents chercheurs : Bernard Meunier, Bruno Canard, Antoine
Danchin et Philippe Marlière. Ils partagent avec vous leurs travaux et
leur vision sur l’histoire, les recherches en cours et les espoirs.
Vous trouverez ici ces
trois articles du numéro de mai publiés en avant-première en ligne :
Covid-19,
ou quand le manque
d’antiviraux efficaces devient un problème mondial, par Bernard Meunier
Covid-19
: la chimie médicinale à
l’assaut des mécanismes de propagation virale, par Bernard Canard
La
cytosine, au cœur de l’immunité
antivirale innée, par Antoine Danchin et Philippe Marlière
|
|
|
 |
Eurofins
Covid-19 Sentinel TM Wastewater Test Provide Early Warning of a
potential COVID-19 outbreak
The Eurofins Covid-19 SentinelTM program was developed to monitor the
evolution of the pandemic and for early detection of outbreaks. The
study objective was to develop a wastewater testing method to analyze
SARS-CoV-2 as an indicator of community infection rate as of resurgence
of COVID-19 in well-defined sites such as production facilities,
hospitals or nursing homes. Eurofins performed >700 tests on 78
unique samples from 18 sites in Denmark, France and Belgium.
https://www.medrxiv.org/content/10.1101/2020.07.10.20150573v2.full.pdf
|
|
Combien de cas de
coronavirus passent sous le radar ? :
How
much is coronavirus spreading under the radar - Nature 200313
|
|
Nouveaus médicaments
et vaccins en cours de développement :
Covid-19
Small Molecule Therapies
Reviewed
Covid-19
Biologic Therapies Reviewed
COVID-19: A
growing list of new
vaccines and therapies in development
|
